Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B Cell Lymphoma

NCT01014208 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

447

Enrollment

INDUSTRY

Sponsor class

Conditions

Lymphoma, Large-Cell, Diffuse

Interventions

DRUG: OFATUMUMAB + DHAP
DRUG: RITUXIMAB + DHAP

Sponsor

GlaxoSmithKline